

Leaning in to Acute Stroke Care in Resource-Limited Settings

July 22nd, 2022

Disclaimer

- “The Emergency Quality Network (E-QUAL) Stroke Initiative is supported through a general research agreement with Genentech – A Member of the Roche Group. Genentech is providing general support to the E-QUAL Network Stroke Initiative but has no ownership in the Emergency Quality Network. The design and dissemination of this research, as well as the selection of content, the use of the Emergency Quality Network, and the selection of findings for publication are at the discretion of the American College of Emergency Physicians. Any opinions stated during the course of this (webinar/podcast) are those of the speaker and do not reflect the opinions of Genentech.”

Matthew S. Siket, MD, MS, FACEP

**Associate Professor, Departments of
Emergency Medicine & Neurological Sciences**

**Associate Program Director of the UVM
Emergency Medicine Residency Program**

**Robert Larner M.D. College of Medicine at the
University of Vermont**



- I receive grant funding from the Telehealth Network Grant Program through HRSA

Objectives

- Discuss how to remain thorough & efficient with acute code stroke processes in rural settings
- Review tools to support decision-making with regards to stroke diagnosis and reperfusion decisions
- Outline the role of the rural community ED, critical access site and ASRH in the larger stroke system-of-care



Where I Live & Work...

- Aging population that values community-based care, yet workforce and geographic challenges the equitable delivery of care



Some Fundamental Truths...


- Time is brain, disability & quality of life
- Designated stroke centers are associated with improved patient outcomes
- Stroke systems-of-care are evolving rapidly and have the potential to markedly reduce the overall burden of disease

Saver JL. Brain 2017
Meretoja A et al. Neurology 2017
Saver JL et al. JAMA 2016
Ganesh A et al. Neurology 2016
Xian Y et al. JAMA 2011
Adeoye O et al. 2019




Justification

- **5th leading cause of death in the US**
- **Leading cause of disability (\$74 billion)**
- **17 million strokes per year (85% ischemic)**
- **Burden of stroke in the US estimated to double by 2050**



■ Death ■ Disability ■ Recovery

Achieving More Rapid Door-to-Needle Times and Improved Outcomes: Target: Stroke Phase I and Phase II



Measure	Period	Event Rate	Adjusted OR (95% CI)
In-hospital Mortality	Pre-intervention	10.0%	Ref
	Phase I	8.2%	0.84 (0.79-0.89)
	Phase II	6.0%	0.69 (0.64-0.73)
sICH ≤ 36 h	Pre-intervention	5.5%	Ref
	Phase I	4.3%	0.79 (0.73-0.86)
	Phase II	3.4%	0.68 (0.62-0.74)
Discharged to home	Pre-intervention	35.7%	Ref
	Phase I	41.5%	1.21 (1.16-1.26)
	Phase II	49.6%	1.43 (1.38-1.50)
Independent ambulation at discharge	Pre-intervention	41.5%	Ref
	Phase I	44.6%	1.08 (1.02-1.15)
	Phase II	53.3%	1.40 (1.32-1.49)
Disability-free (mRS 0-1) at discharge	Pre-intervention	17.8%	Ref
	Phase I	25.3%	1.11 (0.76-1.61)
	Phase II	31.3%	1.08 (1.01-1.16)

Almost All Americans Are Now Within 1 Hour of Good Stroke Care


Feb. 3, 2022, at 8:18 a.m.

- **91%** within an hour drive time to an ASRH or more
- **96%** within an hour to a telestroke capable facility






2446 (44%) stroke centers


- 297 CSCs
- 14 TCSCs
- 1459 PSCs
- 678 ASRHs





<https://www.usnews.com/news/health-news/articles/2022-02-03/almost-all-americans-are-now-within-1-hour-of-good-stroke-care>



- 65,384 tPA treated AIS patients



Time Dependent Effect in LVO



Access to Endovascular Capable Facilities via Ambulance or Helicopter

- In 2015, **10,284** thrombectomies were performed in the US of 31,866 LVOs presenting with LKW<6h and ASPECTS ≥ 6
- In Q3 2016, **27.3%** of eligible patients were treated
- Estimated LVO incidence of 24 (95% CI 20-28) per 100,000

Driving or Flying Time

- 0-60 Minutes
- > 60 Minutes

Population Density

- 1 Dot = 2,500 ppl

Table. Percentage of Americans With 60-Minute Access to r-tPA-Capable Hospitals, Endovascular-Capable Hospitals, and Primary Stroke Centers by Ground and Air Ambulance, Allowing for Crossing State Lines

	60-min Ground Access			60-min Air Access		
	r-tPA Capable, %	Endovascular Capable, %	PSC, %	r-tPA Capable, %	Endovascular Capable, %	PSC, %
Northeast						
New England						
CT	95.6	63.8	89.4	100.0	100.0	100.0
ME	54.5	21.3	31.7	90.0	60.5	88.7
MA	96.3	63.4	9.3	100.0	97.6	96.9
NH	77.1	0.0	0.0	99.6	81.9	74.7
RI	97.5	83.7	96.5	100.0	100.0	100.0
VT	37.1	25.1	25.1	90.7	66.4	66.3
Middle Atlantic						
NJ	98.4	87.0	95.1	100.0	100.0	100.0
NY	91.9	77.4	72.3	99.8	96.0	94.2
PA	85.5	57.8	73.5	100.0	97.5	99.7

Reasons for Failure

- Lack of recognition
- Delay to diagnosis
- Inefficient transfer systems-of-care
- ASPECTS decay during inter-facility transfer
 - Occurred in 1/3 of patients (31%) in one study




A Difficult Ask in Resource-Limited Settings...



- ✓ **Improve access to care**
- ✓ **Expedite time to diagnosis**
- ✓ **Avoid misdiagnosis**
- ✓ **Consider individual preferences of each patient**
- ✓ **Minimize time to definitive management**

Neurology Deserts Are Common...



Top 20 neurology desert states

- Wyoming
- North Dakota
- South Carolina
- South Dakota
- Oklahoma
- Iowa
- Arkansas
- Hawaii
- New Mexico
- Nevada
- Mississippi
- Maine
- Idaho
- Delaware
- Alabama
- Montana
- Kansas
- Vermont
- West Virginia
- Kentucky

How EM & EMS Can Safely & Effectively Lead a Code Stroke Response:




- ✓ **Stroke screening & severity grading in the field**
- ✓ **Regional destination protocols**
- ✓ **Drip and ship or Mothership?**
- ✓ **Grease the wheels to reduce the friction**
- ✓ **Advanced imaging capabilities?**


Field Triage

- AHA Mission: Lifeline severity-based stroke triage for EMS
- Centralized & Coordinated Dispatch
- Mobile Endovascular Teams
- Automated decision support for destination determination

	3ISS	LAMS	CPSSS	VAN	PASS	FAST-ED	RACE
LOC	*		*		*		
Gaze	*		*	*	*	*	*
Face		*				*	*
Arm	*	*	*	*	*	*	*
Grip		*					
Leg							*
Aphasia				*		*	*
Neglect				*		*	*



Emergency Medical Information Sharing Image



Large Vessel Occlusion Scales Increase Delivery to Endovascular Centers Without Excessive Harm From Misclassifications

Table 1. Overall Agreement of LVO Scales With CT Imaging


Scale	Accuracy	Kappa (95% CI)	Sens	Spec	PPV	NPV	AUC	DOR
RACE ≥ 5	0.86	0.51 (0.41–0.60)	0.66	0.90	0.48	0.93	0.78	17.50
LAMS ≥ 4	0.83	0.43 (0.34–0.52)	0.66	0.86	0.48	0.93	0.76	11.80
FAST-ED ≥ 4	0.85	0.49 (0.40–0.58)	0.70	0.88	0.48	0.92	0.79	16.40
PASS ≥ 2	0.81	0.43 (0.34–0.52)	0.71	0.84	0.45	0.93	0.77	12.40
CPSSS ≥ 2	0.81	0.35 (0.26–0.45)	0.56	0.86	0.42	0.91	0.71	7.54

Prevalence =14.5%. AUC indicates area under receiver-operator curve value; CI, confidence interval; CPSSS, Cincinnati Prehospital Stroke Severity Scale; CT, computed tomography; DOR, diagnostic odds ratio; FAST-ED, Field Assessment Stroke Triage for Emergency Destination; LAMS, Los Angeles Motor Scale; LVO, large vessel occlusion; NPV, negative predictive value; PASS, Prehospital Acute Stroke Severity scale; PPV, positive predictive value; RACE, Rapid Arterial Occlusion Evaluation; Sens, sensitivity; and Spec, specificity.

Cortical Symptoms are the Most Predictive

Group A (n=543)	LVO (n=181)	No LVO (n=362)	SEN	SPE	PPV	NPV	ACC
Hemiparesis	153	170	0.85 (0.78–0.89)	0.53 (0.48–0.58)	0.47 (0.42–0.53)	0.87 (0.82–0.91)	0.64
Any cortical symptom	165	108	0.91 (0.86–0.95)	0.70 (0.65–0.75)	0.60 (0.54–0.66)	0.94 (0.90–0.97)	0.77
Aphasia	85	65	0.47 (0.40–0.55)	0.82 (0.78–0.86)	0.57 (0.48–0.65)	0.76 (0.71–0.80)	0.70
Neglect/ gaze deviation	137	65	0.76 (0.69–0.82)	0.82 (0.78–0.86)	0.68 (0.61–0.74)	0.87 (0.83–0.90)	0.80
Cortical symptom AND hemiparesis	142	67	0.79 (0.72–0.84)	0.82 (0.77–0.85)	0.68 (0.61–0.74)	0.88 (0.84–0.92)	0.80
Cortical symptom OR hemiparesis	176	212	0.97 (0.93–0.99)	0.41 (0.36–0.47)	0.45 (0.40–0.51)	0.97 (0.92–0.99)	0.60
	MT (n=109)	No MT (n=434)	SEN	SPE	PPV	NPV	ACC
Hemiparesis	95	228	0.87 (0.79–0.93)	0.48 (0.43–0.52)	0.29 (0.25–0.35)	0.94 (0.89–0.96)	0.55
Any cortical symptom	98	175	0.90 (0.82–0.95)	0.60 (0.55–0.64)	0.36 (0.30–0.42)	0.96 (0.93–0.98)	0.66
Aphasia	44	106	0.40 (0.31–0.50)	0.76 (0.71–0.80)	0.29 (0.22–0.37)	0.84 (0.79–0.87)	0.69
Neglect/gaze deviation	87	115	0.80 (0.71–0.87)	0.74 (0.69–0.78)	0.43 (0.36–0.50)	0.94 (0.90–0.96)	0.75
Cortical symptom AND hemiparesis	89	120	0.82 (0.73–0.88)	0.72 (0.68–0.77)	0.43 (0.36–0.50)	0.94 (0.91–0.96)	0.74
Cortical symptom OR hemiparesis	104	284	0.95 (0.90–0.98)	0.35 (0.30–0.39)	0.27 (0.23–0.32)	0.97 (0.92–0.99)	0.47


Drip n' Ship or Mothership?




• Modelling dependent on:

- D2N and DIDO times at PSC/ASRH
- D2N and D2G times at TSC/CSC
- Reperfusion rates at TSC/CSC


Model Favors Mothership when recanalization rates ~90%




20min




30min



90min




120min



“No Brainer”

- **Conditions required for drip n’ ship to be preferred:**


- ✓ Longer onset-to-first medical response
- ✓ PSC D2N times < 30 min
- ✓ PSC DIDO times < 50 min
- ✓ CSC D2N times >60 min
- ✓ CSC Door-to-reperfusion time >200 min
- ✓ Transport time > 45 min



Developing a statewide protocol to ensure patients with suspected emergent large vessel occlusion are directly triaged in the field to a comprehensive stroke center: how we did it


Mahesh V Jayaraman,^{1,2,3} Arshad Iqbal,⁴ Brian Silver,² Matthew S Siket,⁵ Caryn Amedee,² Ryan A McTaggart,¹ Gino Paolucci,⁵ Jason Rhodes,⁶ John Potvin,⁷ Megan Tucker,⁸ Nicole Alexander-Scott⁶

- **State Stroke Task Force Initiative**
- **Implementation of EMS LAMS**
- **Destination protocols**
- **Streamlined inter-facility transfer process**





EMERGENCY MEDICAL SERVICES ACUTE STROKE ROUTING




Jauch EC et al. Stroke 2021



American Stroke Association
A division of the American Heart Association.

Together to End Stroke®

Stroke Rural Transport Recommendations



Balance SNS & SPC...Think of Distributive Justice

EMPOWER & SUPPORT THE TEAM:

- Potential reperfusion decision?
- Deficits ongoing, focal & disabling?
- Evidence of a clear mimic?
- Are symptoms positive or negative?

UVMHN STROKE ALERT ACTIVATION CRITERIA

Activate
STROKE ALERT
if

Obtain
LKW

1. Any new, ongoing focal neurologic deficit of <4.5 hours duration & potential tPA candidate
- or
2. Any new, ongoing significant neurologic deficit <24 hours duration, such as:

- NIHSS>4 or
- Prehospital FAST-ED scale 4-5
- Unilateral weakness (face, arm, or leg) or
- Visual field cut or
- Aphasia or Dysarthria
- Neglect

All Stroke Alerts must have a confirmed
time LKW < 24 hours ago

- ED PHYSICIAN:** Briefly assess ABCs to ensure airway & hemodynamic stability and confirm the presence of ongoing focal stroke symptoms, then enter orders using the 'ED STROKE ORDERSET' including appropriate imaging
- NEUROLOGY TEAM:** Perform brief assessment of ongoing focal neurologic deficits (NIHSS) and determine whether perfusion imaging is indicated. Confirm LKW and any tPA contraindications
- ED NURSING:** Obtain POCT glucose. Ensure working peripheral IV appropriate for CTA and obtain patient weight prior to CT
- REGISTRATION:** Quickly register the patient

Spend a Moment Considering Atypical & Subtle Presentations



Acute Dizziness Triage Algorithm

1. Does the patient have acute and sustained dizziness of <24 hours duration?

- As opposed to episodic or triggered episodes that completely resolve between events. **Only abrupt onset and sustained dizziness that has not resolved should be considered as a possible acute stroke**

Yes

2. Is there any additional neurologic deficit (except horizontal nystagmus)?

- Deficits may be subtle. Examples include: double vision or vision loss, slurred speech, inability to sit or stand independently, ataxia, vertical or direction-changing nystagmus, dysmetria (on finger-to-nose or heel-to-shin test), loss of coordination, unilateral weakness or sensory loss, decreased level of consciousness or inattention/neglect

Yes

No

CODE STROKE

3. Are signs of a non-stroke diagnosis present?

- Examples include, but are not limited to: cardiac arrhythmia, hypotension, intoxication

Yes

No

**Not likely an acute
stroke - triage
appropriately**

Yes

4. Are signs of peripheral vertigo present?



- Including horizontal, unidirectional nystagmus, which should always be present in patients with acute and ongoing vertigo from a peripheral cause. Tinnitus and unilateral ear fullness are also suggestive. The ED provider should consider performing the full HINTS exam to differentiate central from peripheral causes.

No

- HINTS** stands for Head Impulse test, Nystagmus, and Test of Skew. The presence of horizontal, unidirectional nystagmus **AND** a positive head impulse test **AND** the absence of vertical skew deviation confirms a peripheral cause (such as vestibular neuronitis)

CODE STROKE



Work in Parallel – Singularly Activate



$$R = R_1 + R_2 + R_3;$$

$$U = U_1 + U_2 + U_3;$$


$$I = I_1 = I_2 = I_3.$$



$$\frac{1}{R} = \frac{1}{R_1} + \frac{1}{R_2} + \frac{1}{R_3};$$

$$I = I_1 + I_2 + I_3;$$

$$U = U_1 = U_2 = U_3.$$



- EMS
- ED Provider
- ED Nurse
- Registration
- Radiology
- Lab
- Tele-Neurology?
- Pharmacy?
- ED Tech?

Minimize steps & handoffs



WHAT MAKES SENSE FOR YOU?

- Can you collect data prior to arrival?
- Designated stroke pitstop?
- ED Resource nurse?
- Stretcher scale outside of CT?
- One-stop for all imaging
- tPA mixing at the bedside or in pharmacy?
- Eliminate excessive checkbacks?
- Hold EMS for possible re-routing?
- Early / one call activation of NIR team?

Cut the fat!

FOCUS ON WHAT MATTERS MOST!

- Old habits die hard..

Design a Process, Test & Refine

	EMS Pre-Notification	0 to 10 minutes	10 to 20 minutes	20 to 30 minutes	30 to 45 minutes	45+ minutes
Priorities:	Activate Code Stroke, Register Patient & Enter Orders	Rapid Triage, Brief Exam, Non Contrast CT Scan	Advanced Imaging, Full History, NIHSS, Labs Drawn & Sent	Determine IV eligibility (Goal: Door to Alteplase ≤30 min)	Determine IA eligibility (Goal: Door to Groin Puncture ≤60 min)	Post-alteplase monitoring if given & transfer to NIR or inpatient unit
ED MD	<ul style="list-style-type: none"> Obtain Name & DOB from EMS If last known normal (LKN) is <24 + ≥1 focal stroke s/s, ACTIVATE CODE STROKE. Include ETA, age, stroke s/s and LKN Activate ED Adult Stroke Initial Evaluation Orders 	<ul style="list-style-type: none"> Verify Blood Glucose result obtained by EMS (if <60mg/dL don't go directly CT) Brief Neuro Exam within 1st 10min If no pre-notification received: If LKN is <24 + ≥1 focal stroke s/s, ACTIVATE CODE STROKE. Include ETA, age, stroke s/s and LKN Activate ED Adult Stroke Initial Evaluation Orders 	<ul style="list-style-type: none"> Maintain SBP ≤185 and DBP ≤110 if reperfusion candidate Implement Hemorrhagic Stroke orders if needed based on CT results Manage Overall Care Brief update to patient/caregiver Transport to assigned room Verify/initiate IV access (2 if possible) Draw Labs 	<ul style="list-style-type: none"> Maintain SBP ≤185 and DBP ≤110 Manage overall care, review labs, ECG Vital Signs: BP & HR Strict NPO Obtain 2nd IV for alteplase If Alteplase Candidate: Notify ED MD & NEU for BP ≥185/110 	<ul style="list-style-type: none"> Maintain SBP ≤185 and DBP ≤110 Manage overall care, review ECG For Alteplase treated patients: Maintain SBP ≤180 and DBP ≤105 Monitor for post-alteplase complications If Alteplase Administered: Continue post-alteplase Neuro assessment and VS protocol Continue post-alteplase Neuro assessment and VS protocol Monitor post-alteplase complications Nursing Bedside Dysphagia Screen: if pass may administer meds, obtain diet order; if fail STRICT NPO If MT Candidate: Transport to NIR, handoff to anesthesia/NIR nurse at bedside If Intra-Arterial Candidate: Complete advanced imaging, (if not done) Send final treatment decision and transport decision updates Code MT Pagers Communicate treatment plan to ED RN/MD Communicate treatment plan to Patient/Family Facilitate rapid transport to NIR to facilitate groin puncture by 60 minutes 	<ul style="list-style-type: none"> For Alteplase treated patients: Maintain SBP <180 and DBP <105 Monitor for post-alteplase complications If Alteplase Administered: Continue post-alteplase Neuro assessment and VS protocol Hang normal saline <u>at same rate</u> when alteplase complete to flush line Monitor post-alteplase complications Nursing Bedside Dysphagia Screen: if pass may administer meds, obtain diet order; if fail STRICT NPO Transfer to ICU/stroke unit when bed available (unless MT candidate) If Alteplase not administered: Nursing Bedside Dysphagia Screen: if pass may administer meds, obtain diet order; if failed STRICT NPO Transfer to stroke unit when available Write consult note/ H&P using template (include time seen, time of image(s) review, NIHSS) If Alteplase given: Consult Neuro ICU team & enter place patient in ICU or stroke unit bed order If Alteplase not given: ASA 300mg PR (if nursing bedside screen failed) ASA 325mg PO (if nursing bedside screen passed)
ED RN	<ul style="list-style-type: none"> Obtain name & DOB from EMS If last known normal (LKN) is <24 + ≥1 focal stroke s/s, ACTIVATE CODE STROKE. Include ETA, age, stroke s/s and LKN 	<ul style="list-style-type: none"> Rapid Triage Obtain Vital Signs from EMS monitor Notify ED MD for BP ≥185/110 Place ID band on patient Obtain Blood Glucose (if not done by EMS) & notify ED MD of results Transport to CT Scan on EMS stretcher If no pre-notification received: Contact ED Registration for STAT registration Contact ED Registration for STAT registration Obtain alteplase kit 	<ul style="list-style-type: none"> If patient is on warfarin obtain POC INR Send Labs with red 'Code Stroke Alert' Obtain POC Glucose Full set of Vitals, oxygen saturation Neuro Assessment Cardiac Monitoring Obtain & document patient weight Begin Stroke Narrator Documentation 	<ul style="list-style-type: none"> Complete independent double check and waste excess Draw up bolus into syringe Administer bolus and infusion per order & protocol Implement post-alteplase Neuro assessment and VS protocol: <ul style="list-style-type: none"> Strict NPO <ul style="list-style-type: none"> Q 15min x 2 hrs Q 30min x 6hrs Q 1 hr x 16 hrs 	<ul style="list-style-type: none"> Review ECG, Lab Results (BG is only required test if not on anticoagulation and no history of blood dyscrasias) If Alteplase Candidate: Verify SBP ≤185mmHG and DBP ≤110mmHG. Treat if needed. Notify ED RN to begin mixing drug Review risks/benefits/ alternatives with pt/caregiver & provide education Communicate plan of care to ED MD/RN Use ED STROKE orderset to order alteplase Notify ED RN/Pharmacist when order is placed & verify dose with RN/Pharmacist Consult Neuro ICU team & enter place patient in ICU or stroke unit bed order 	<ul style="list-style-type: none"> Transfer to stroke unit when available Write consult note/ H&P using template (include time seen, time of image(s) review, NIHSS) If Alteplase given: Consult Neuro ICU team & enter place patient in ICU or stroke unit bed order If Alteplase not given: ASA 300mg PR (if nursing bedside screen failed) ASA 325mg PO (if nursing bedside screen passed)
Neurologist/Resident/Tele Neuro	<ul style="list-style-type: none"> Respond to ED Triage to meet patient Order CTA as necessary if pt is a possible LVO Stroke/Code MT* If LKN 6-24 hours, consider CTP (perform at same time as CTA) <p><i>When CTA/CTP is ordered, place cerebral angiogram order and initiate Code MT Stroke Physician Workflow. Page Possible Code MT if LVO scale positive</i></p>	<ul style="list-style-type: none"> Obtain history from EMS en route to CT Obtain family/witness contact info from EMS Determine advanced imaging plan (CTA, CTP) & place orders as needed - DO NOT delay alteplase administration for advanced imaging Initial NC Head CT read. Implement Hemorrhagic Stroke Pathway as needed If patient is on warfarin, notify RN to obtain POC INR If no pre-notification received: Receive Code Stroke Page and respond directly to ED/CT Scan, determine need for CTA/CTP 	<ul style="list-style-type: none"> Initiate advanced imaging plan (if needed) If advanced imaging ordered, page 'possible Code MT' NIHSS & Determine focal/stroke related deficits Document ABCD2 score, follow TIA protocol Consult with Radiologist for final interpretation of NC Head CT Scan if needed Based on CT results and exam, determine inclusion, exclusion and warning criteria for IV alteplase. Finalize treatment plan no later than 20 minutes after patient arrival 	<ul style="list-style-type: none"> Review ECG, Lab Results (BG is only required test if not on anticoagulation and no history of blood dyscrasias) If Alteplase Candidate: Verify SBP ≤185mmHG and DBP ≤110mmHG. Treat if needed. Notify ED RN to begin mixing drug Review risks/benefits/ alternatives with pt/caregiver & provide education Communicate plan of care to ED MD/RN Use ED STROKE orderset to order alteplase Notify ED RN/Pharmacist when order is placed & verify dose with RN/Pharmacist Consult Neuro ICU team & enter place patient in ICU or stroke unit bed order 	<ul style="list-style-type: none"> Review ECG, Lab Results (BG is only required test if not on anticoagulation and no history of blood dyscrasias) If Alteplase Candidate: Verify SBP ≤185mmHG and DBP ≤110mmHG. Treat if needed. Notify ED RN to begin mixing drug Review risks/benefits/ alternatives with pt/caregiver & provide education Communicate plan of care to ED MD/RN Use ED STROKE orderset to order alteplase Notify ED RN/Pharmacist when order is placed & verify dose with RN/Pharmacist Consult Neuro ICU team & enter place patient in ICU or stroke unit bed order 	<ul style="list-style-type: none"> Transfer to stroke unit when available Write consult note/ H&P using template (include time seen, time of image(s) review, NIHSS) If Alteplase given: Consult Neuro ICU team & enter place patient in ICU or stroke unit bed order If Alteplase not given: ASA 300mg PR (if nursing bedside screen failed) ASA 325mg PO (if nursing bedside screen passed)

Adapted courtesy of The University of North Carolina Comprehensive Stroke Center

Analysis of Thrombolysis Process for Acute Ischemic Stroke in Urban and Rural Hospitals in Nova Scotia Canada


Suggested Improvements

Pre-hospital

- Site 1 (Urban)
 - More direct information from paramedics (patient identity, clarity of problem, when possible more lead-time)
 - Modern secure telecom/video streaming systems for transmission of information of paramedic's assessment
 - EMS to put in two IVs before arriving to ED
- Site 2 (Rural)
 - EMS to automatically communicate patient identifiers
 - EMS getting patient's next of kin information and instructing them to go directly to hospital (or being easily accessible via their phone)
- Site 3 (Rural)
 - EMS triage
 - EMS availability

Hospital-based

- Site 1 (Urban)
 - Stroke nurse available at all times (tPA administered in CT department)
 - Alternatively, have an ED nurse travel with patient to imaging (tPA administered in CT department)
 - tPA stored within CT department in locked drug cupboard
 - Use INR point-of-care machine prior to imaging
 - Wait to collect blood sample until after imaging
- Site 2 (Rural)
 - Obtain INR point-of-care machine
 - Have patient's medication list automatically printed out (currently done by ED physician)
 - Bloodwork collected and 2nd IV put in on EMS stretcher before imaging
 - Obtain 2nd CT scanner
 - Improve communication among healthcare professionals
 - Increase emphasis on continuing education
- Site 3 (Rural)
 - Mix tPA and have treatment discussion while patient in scanner
 - Remove NG tube and Foley catheter requirement before tPA administration
 - Registration clerk and CT technologist in-hospital at all times
 - Clarification on which patients require CTA scan
 - Increase education piece to improve ED physician comfort with giving tPA



Shifting Bottlenecks





Figure 1 Shifting bottlenecks: the individual steps from first medical contact to final recanalization. Each pose potential rate-limiting steps in achieving fast reperfusion. Initial bottlenecks were faced in achieving fast recanalization and patient selection. With improvements at nearly every step, the remaining significant bottleneck is now in-field patient triage. BRISK, Brisk Recanalization Ischemic Stroke Kit; CTP, CT perfusion; GA, general anesthesia; LVO, large vessel occlusion.

What Imaging Works Best for You?

- Direct-to-CT?
- CT/CTA?
- Perfusion (CT or MR)?
- Field-based imaging?
- Direct-to-MR?
- Direct-to-Angio?



A 78 Seconds Complete Brain MRI Examination in Ischemic Stroke: A Prospective Cohort Study





Figure 3. Primary Stroke Center (PSC) Emergent Large-Vessel Occlusion (ELVO) Protocol Care Efficiency Metrics



- **40 minute reduction in DIDO time (p<.001)**
- **Twice as likely to have a favorable outcome (50% vs. 25%, P<.04)**


Reasons to Activate Neurology Expertise Early:

- ASRH designation states telemedicine “within 20 minutes of it being necessary”
- To assist in parallel-processing (review imaging, chart review for exclusion criteria to thrombolysis, patient examination and documentation)
- To confirm inclusion criteria for thrombolysis / thrombectomy
- To expedite interfacility transfer when necessary
- Earlier notification appears to streamline downstream processes




Reduce Barriers to Stroke Expertise

- Among 153,272 stroke patients 2008-2017, those treated at telestroke hospitals were more likely to receive reperfusion treatment and had lower 30-day mortality




Practice Makes Perfect

- Among 67,736 telestroke calls at 132 sites between 2013-2019 – longer duration of participation was associated with shorter D2N times (39 min shorter per year, $p=0.04$)



No Telestroke? – Keep it Simple

- Time LKW
- Description of ongoing deficits (NIHSS-ish)
- Blood glucose, vital signs
- Pertinent imaging findings
- Contraindications to thrombolysis



Summary of Current Contraindications to tPA

Nondisabling symptoms

Extensive/severe hypoattenuation on CT

Recent Ischemic stroke w/i 3 months

ICH on CT or hx of ICH/SAH

Acute head trauma (or severe w/i 3 months)

Intracranial/spinal surgery w/i 3 months


Coagulopathy (warfarin with INR>1.7, oral anticoagulant use w/i 48 hours or coag studies are normal, full dose heparin/LMWH within 24 hours). Do not generally wait for platelet count and coag studies, but do not administer if platelet count is known to be <100,000/mm³, INR>1.7, aPTT>40s, or PT>15s

Current intracranial neoplasm, infective endocarditis, aortic arch dissection, GI malignancy

GI bleeding w/i 21 days


Discussing Risks & Benefits of tPA

- Opportunity for consensus language that conveys an institutional standard rather than placing pressure on providers in the moment
- This shows the 3 month outcomes of 100 patients treated within 3 hours of stroke onset:
 - Patients treated with tPA are between 1.5 and 2x as likely to return to normal or near normal function at 3 months
 - 1 in 7 patients who receive tPA have an improvement in outcome due to the drug
 - The effects of the drug are time-dependent. If the drug can be given within 1.5 hours of onset, the chance of improvement increases to 1 in 3
 - 1 in 18 patients who received tPA had significant bleeding due to the drug
 - The risk of dying from the stroke is similar regardless of the treatment
 - tPA increases the chances of functional independence, but with a 10-fold increase in risk of bleeding



Can we better predict individual clinical response to thrombolysis?

- iScore applied to >12,000 patients at 154 sites
- iScore ≥ 200 : NNT 385, NNH 5-17; $p < 0.05$
- Validated in NINDS cohort:



Name: _____

Date: 25 January 2019

ISCORE

GCS

CNS

Ischemic Stroke Predictive Risk Score

Calculator

Print Clear Calculate

Check if you need help to estimate stroke severity (CNS)

Manual CNS/NHSS entry: CNS NHSS

ISCORE

Age: years

Sex: Male Female

Stroke Severity: CNS

Stroke Subtype: Lacunar

Risk Factors

Atrial fibrillation

CHF

Previous myocardial infarction

Current smoker

Comorbid Conditions

Cancer

Renal disease on dialysis

Preadmission Disability

Dependent

Glucose on Admission

≥ 7.5 mmol/L (>135 mg%)

Outcomes: Mortality

30 Day Mortality

ISCORE Mortality %

1 Year Mortality

ISCORE Mortality %

Functional Outcomes at Discharge

30 Day Death or Disability

ISCORE Death or Disability %

30 Day Death or Institutionalization

ISCORE Death or Institutionalization %

Death was captured up to 30-days post-discharge

Thrombolytic Therapy

Probability of Good Clinical Outcome (mRS 0-2)

Prevalence

Outcomes


Ensuring Diagnostic Accuracy

- **Prioritize assessment to measuring ongoing focal neurologic deficits:**
 - ▶ Negative symptoms suggest ablative phenomena – i.e stroke
 - ▶ Positive symptoms suggest irritative / non-ischemic phenomena
- **When tPA is given to a stroke mimic, complications are rare:**
 - ▶ Among a cohort of 72,582 tPA treated patients from 2010-2017:
 - ▶ sICH 0.4% (aOR 0.29; 95% CI, 0.17-0.50) vs. 3.5% in stroke
 - ▶ In-hospital mortality 0.8% (aOR 0.31; 95% CI, 0.20-0.49) vs. 6.2% in stroke

	Stroke Mimics N=2517	Ischemic Stroke N=70 065	Adjusted OR (95% CI)	P Value
Safety end points				
Symptomatic intracranial hemorrhage	11 (0.4)	2451 (3.5)	0.29 (0.17–0.50)	<0.001
Life-threatening or serious systemic hemorrhage	1 (0)	516 (0.7)	0.15 (0.03–0.84)	0.03
Other serious complication	26 (1.0)	1938 (2.8)	0.73 (0.51–1.03)	0.08
Any tPA complication*	38 (1.5)	4803 (6.9)	0.48 (0.36–0.64)	<0.001

Should tPA be Used in Minor Nondisabling Stroke?

- PRISMS trial terminated after 313/948 enrolled
- NIHSS 0-5 AND deficits “not clearly disabling”
- No significant difference in mRS 0-1 at 90 days
- sICH 3.2% vs. 0% (risk diff, 3.3%, 95%CI 0.8-7.4)



Khatri P et al. JAMA 2018

Characteristics	No. (%)	
	Intravenous Alteplase + Oral Placebo (n = 156)	Intravenous Placebo + Oral Aspirin (n = 157)
Rapid improvement of symptoms prior to study treatment administration	8 (5.1)	7 (4.5)
Localization of presenting deficit ^a		
Right hemisphere	75 (48.1)	67 (42.7)
Left hemisphere	59 (37.8)	62 (39.5)
Unknown	19 (12.2)	21 (13.4)
Brainstem/cerebellum	9 (5.8)	18 (11.5)
Final diagnosis		
Acute cerebral ischemia	136 (88.3)	131 (85.6)
Neurovascular mimic ^b	18 (11.7)	22 (14.4)
Ischemic cerebral event etiology ^c	n=138	n=135
Small vessel disease	48 (34.8)	52 (38.5)
Undetermined etiology	40 (29.0)	46 (34.1)
Cardioembolism	20 (14.5)	17 (12.6)
Large artery atherosclerosis	20 (14.5)	10 (7.4)
Other determined etiology ^d	10 (7.2)	10 (7.4)

Be Vigilant for Deterioration or Complication

Table 6. Management of Symptomatic Intracranial Bleeding Occurring Within 24 Hours After Administration of IV Alteplase for Treatment of AIS

COR IIb	LOE C-E0
Stop alteplase infusion	
CBC, PT (INR), aPTT, fibrinogen level, and type and cross-match	
Emergent nonenhanced head CT	
Cryoprecipitate (includes factor VIII): 10 U infused over 10–30 min (onset in 1 h, peaks in 12 h); administer additional dose for fibrinogen level of <150 mg/dL	
Tranexamic acid 1000 mg IV infused over 10 min OR ε-aminocaproic acid 4–5 g over 1 h, followed by 1 g IV until bleeding is controlled (peak onset in 3 h) (Potential for benefit in all patients, but particularly when blood products are contraindicated or declined by patient/family or if cryoprecipitate is not available in a timely manner.)	
Hematology and neurosurgery consultations	
Supportive therapy, including BP management, ICP, CPP, MAP, temperature, and glucose control	

AIS indicates acute ischemic stroke; aPTT, activated partial thromboplastin time; BP, blood pressure; CBC, complete blood count; COR, class of recommendation; CPP, cerebral perfusion pressure; CT, computed tomography; ICP, intracranial pressure; INR, international normalized ratio; IV, intravenous; LOE, Level of Evidence; MAP, mean arterial pressure; and PT, prothrombin time.

Sources: Sloan et al,¹³⁸ Mahaffey et al,¹³⁹ Goldstein et al,¹⁴⁰ French et al,¹⁴¹ Yaghi et al,^{142–144} Stone et al,¹⁴⁵ and Frontera et al.¹⁴⁶

Table 7. Management of Orolingual Angioedema Associated With IV Alteplase Administration for AIS

COR IIb	LOE C-E0
Maintain airway	
Endotracheal intubation may not be necessary if edema is limited to anterior tongue and lips.	
Edema involving larynx, palate, floor of mouth, or oropharynx with rapid progression (within 30 min) poses higher risk of requiring intubation.	
Awake fiberoptic intubation is optimal. Nasal-tracheal intubation may be required but poses risk of epistaxis after IV alteplase. Cricothyroidotomy is rarely needed and also problematic after IV alteplase.	
Discontinue IV alteplase infusion and hold ACE inhibitors	
Administer IV methylprednisolone 125 mg	
Administer IV diphenhydramine 50 mg	
Administer ranitidine 50 mg IV or famotidine 20 mg IV	
If there is further increase in angioedema, administer epinephrine (0.1%) 0.3 mL subcutaneously or by nebulizer 0.5 mL	
Icatibant, a selective bradykinin B ₂ receptor antagonist, 3 mL (30 mg) subcutaneously in abdominal area; additional injection of 30 mg may be administered at intervals of 6 h not to exceed a total of 3 injections in 24 h; and plasma-derived C1 esterase inhibitor (20 IU/kg) has been successfully used in hereditary angioedema and ACE inhibitor-related angioedema	
Supportive care	

ACE indicates angiotensin-converting enzyme; AIS, acute ischemic stroke; COR, class of recommendation; IV, intravenous; and LOE, Level of Evidence.

Sources: Foster-Goldman and McCarthy,¹⁴⁷ Gorski and Schmidt,¹⁴⁸ Lewis,¹⁴⁹ Lin et al,¹⁵⁰ Correia et al,¹⁵¹ O'Carroll and Aguilar,¹⁵² Myslimi et al,¹⁵³ and Pahs et al.¹⁵⁴

- Intra- and post tPA monitoring is time intensive!
 - ▶ Serial neurologic assessments and vital signs every 15 min for 2 hours, then every 30 min for 6 hours, then hourly until 24 hours post tPA
- Have a readily accessible protocol for sICH and orolingual edema

Ensure Appropriate Disposition

- Organized stroke unit care is associated with improved outcomes (OR 0.77; 95% CI, 0.69-0.87)
- If no dedicated stroke unit, be sure to do the basics well:
 - ▶ Control fever, blood glucose and aspiration risk




Figure 3: Distribution of 90-day modified Rankin scale*

*Percentages may not total to 100% due to rounding.

- NNT 6.4 to prevent death or significant disability at 90 days

Keep the Wheels Greased

- **Education, simulation & feedback are critical at low volume centers**
- **Focusing on OTT and DIDO ensures stakeholders are mindful to the entire stroke chain of survival**
- **For many resource-limited settings EMS holds the key to efficiency on the front & back end**



Strategies to streamline interfacility transfers

- Hold EMS when transfer suspected prior to arrival
- Auto accept at regional hub
- Consider ‘give and go’ instead of ‘drip and ship’
 - ▶ Tenecteplase appears to be non-inferior to alteplase and has been shown to reduce D2N and DIDO times
 - ▶ Bolus only dose over 5-10 seconds

	Entire Sample			Class 1 Subgroup		
	ALT (n=354)	TNK (n=234)	P value	ALT (n=219)	TNK (n=143)	P value
Door-in-door-out (DIDO)						
Minutes	135 (100, 177)	113 (83, 153)	.054	126 (98, 167)	88 (83, 182)	.3
n =	65	43		32	9	
within 90 min	9 (14%)	16 (37%)	.010	4 (12%)	5 (56%)	.014
Needle to door out time						
Minutes	58 (32, 108)	42 (28, 74)	.13	61 (37, 112)	42 (36, 121)	.5
n =	67	43		33	9	
within 60 minutes	34/65 (52%)	29 (67%)	.2	16/32 (50%)	6 (67%)	.5



Take Home Points

- Exceptional ED stroke care is achievable in resource-limited settings
- Requires alignment of the system-of-care including prehospital severity grading and destination protocols
- Align early ED priorities to streamline time to diagnosis when a reperfusion decision is to be made
- Involve neurologic expertise by telemedicine or phone early
- Be mindful of the impact of DIDO and downstream efficiency on optimizing patient outcomes



Thank You

Matthew.Siket@uvmhealth.org
@SiketMD